Regorafenib

瑞戈非尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameRegorafenib
Drug Alias Namefluoro-sorafenib瑞戈菲尼瑞格非尼regorafenib瑞格菲尼 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTEK receptor tyrosine kinase antagonistsVascular endothelial growth factor receptor 3 antagonistsNerve growth factor receptor Trk-A antagonists +[20] 
TargetsVascular endothelial growth factor receptor 1Ephrin type-A receptor 2Stem cell growth factor receptor +[20] 
Therapy Area/IndicationsEsophageal adenocarcinomaSolid tumoursNeoplasm Metastasis +[40] 
Global Approved IndicationsColorectal NeoplasmsCarcinoma, Hepatocellular
Approved Indications in ChinaColorectal NeoplasmsCarcinoma, Hepatocellular
Original Approved Country/TerritoryUnited States
Original Approved Date2012/09/27
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer Pharma AgDana-Farber Cancer InstituteInstitute Of Mother And Child +[17] 
Inactive CompaniesUtah State UniversityGeorgetown UniversityRoswell Park Cancer Institute +[17] 
Active IndicationsSolid tumoursNeoplasm MetastasisThyroid Neoplasms +[19] 
Inactive IndicationsEsophageal adenocarcinomaFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[21] 

Other Information

ATC CodeL01EX05
Related LinksWikipediaDrugBankKEGG